• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Neurogene Inc.

    11/14/24 6:22:47 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NGNE alert in real time by email
    SC 13G 1 p24-3250sc13g.htm NEUROGENE INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  )*
     

    Neurogene Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.000001 per share

    (Title of Class of Securities)
     

    64135M105

    (CUSIP Number)
     

    September 30, 2024

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 64135M10513GPage 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    1,135,256 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    1,135,256 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,135,256 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.7%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    CUSIP No. 64135M10513GPage 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Roderick Wong, M.D.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    1,135,256 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    1,135,256 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,135,256 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.7%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. 64135M10513GPage 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Neurogene Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 535 W 24th St., 5th Floor, New York, New York 10011.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:

     

      (i)

    RTW Investments, LP ("RTW Investments"), a Delaware limited partnership, and the investment adviser to certain funds (the "RTW Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the RTW Funds; and

     

      (ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

     

    Item 2(c). CITIZENSHIP:
       
      RTW Investments is a Delaware limited partnership.  Dr. Wong is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.000001 per share (the "Shares").

     

    Item 2(e). CUSIP NUMBER:
       
      64135M105

     

    CUSIP No. 64135M10513GPage 5 of 7 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                            

     

    Item 4. OWNERSHIP:
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
       
      The percentages set forth herein are calculated based upon 12,993,613 Shares outstanding as of August 5, 2024, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 9, 2024.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      Not applicable.

     

    CUSIP No. 64135M10513GPage 6 of 7 Pages

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2.  The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 64135M10513GPage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: November 14, 2024

     

     

    RTW INVESTMENTS, LP
       
       
    By: /s/ Roderick Wong, M.D.  
    Name: Roderick Wong, M.D.  
    Title: Managing Partner  
       
       
       
    /s/ Roderick Wong, M.D.  
    RODERICK WONG, M.D.  

     

     

     

    Get the next $NGNE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NGNE

    DatePrice TargetRatingAnalyst
    6/17/2025$50.00Buy
    Craig Hallum
    5/16/2025$24.00Outperform → Neutral
    Robert W. Baird
    6/27/2024$65.00Outperform
    BMO Capital Markets
    6/11/2024$54.00Outperform
    Robert W. Baird
    4/29/2024$46.00Outperform
    Leerink Partners
    3/21/2024$61.00Outperform
    William Blair
    More analyst ratings

    $NGNE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025

    Completed discussions with FDA on registrational protocol; 13 sites to allow for rapid enrollment New preclinical data at ESGCT Congress highlight NGN-401 best-in-class potential and add to body of evidence that ICV administration is superior to IT-L in reaching key brain regions underlying Rett syndrome As previously reported, the first four participants in the NGN-401 Phase 1/2 trial gained 23 developmental milestones/skills, representing multi-domain improvement that requires transduction of key brain regions and nervous system The preclinical data also provide evidence-based confirmation that ICV and IT-L administration result in comparable peripheral organ transduction, showing n

    10/9/25 7:00:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

    Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright Genetic Medicines Virtual Conference. Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, October 14 at 7:00 a.m. ET A webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene's website under events, where a replay of the event will also be available for a limited time. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to imp

    10/8/25 7:30:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 9,390 shares of the Company's common stock to four new employees (the "Inducement Grants") on October 1, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance w

    10/3/25 4:01:00 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Baffi Robert

    4 - Neurogene Inc. (0001404644) (Issuer)

    6/13/25 12:07:42 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Woods Robert Keith

    4 - Neurogene Inc. (0001404644) (Issuer)

    6/13/25 12:07:13 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Palekar Rohan

    4 - Neurogene Inc. (0001404644) (Issuer)

    6/13/25 12:06:44 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Samsara Biocapital Gp, Llc bought $1,259,623 worth of shares (48,770 units at $25.83) (SEC Form 4)

    4 - Neurogene Inc. (0001404644) (Issuer)

    11/27/24 4:39:29 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CFO Cvijic Christine Mikail bought $491,400 worth of shares (24,000 units at $20.48), increasing direct ownership by 45% to 76,844 units (SEC Form 4)

    4 - Neurogene Inc. (0001404644) (Issuer)

    11/25/24 9:29:29 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Mcminn Rachel bought $969,000 worth of shares (47,500 units at $20.40), increasing direct ownership by 4% to 1,297,859 units (SEC Form 4)

    4 - Neurogene Inc. (0001404644) (Issuer)

    11/25/24 9:29:04 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Neurogene with a new price target

    Craig Hallum initiated coverage of Neurogene with a rating of Buy and set a new price target of $50.00

    6/17/25 8:10:28 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Neurogene from Outperform to Neutral and set a new price target of $24.00

    5/16/25 8:03:18 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets initiated coverage on Neurogene with a new price target

    BMO Capital Markets initiated coverage of Neurogene with a rating of Outperform and set a new price target of $65.00

    6/27/24 7:50:19 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    SEC Filings

    View All

    Neurogene Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Neurogene Inc. (0001404644) (Filer)

    10/9/25 7:01:21 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Neurogene Inc.

    SCHEDULE 13G/A - Neurogene Inc. (0001404644) (Subject)

    8/14/25 4:27:25 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Neurogene Inc.

    424B5 - Neurogene Inc. (0001404644) (Filer)

    8/11/25 4:48:06 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Leadership Updates

    Live Leadership Updates

    View All

    Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

    Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of Rett syndrome. As previously disclosed, on November 11, 2024, Neurogene became aware of an emerging treatment-related serious adverse event (SAE) in a trial participant who received NGN-401 at a dose of 3E15 vg (high-dose cohort). This participant, who was dosed on November 5, subsequently experienced signs of a systemic hyperinflammatory syndrome, a rare and life-threatening immune response tha

    11/18/24 6:45:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

    Expanded Phase 1/2 gene therapy trial for Rett syndrome to inform future registrational study design; Company remains on track to share interim clinical data in 4Q:24 Strong financial position with runway into 2H:26 following reverse merger and private financing in December 2023 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates. "We started the year with strong execution in our Phase 1/2 NGN-401 gene therapy trial for female pediatric patients with Rett syndrom

    3/18/24 4:14:00 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Financials

    Live finance-specific insights

    View All

    Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

    All participants experienced a 2-point improvement in the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale from baseline All participants improved in the caregiver-completed Rett Syndrome Behavior Questionnaire (RSBQ), ranging from 28 to 52 percent improvement from baseline All participants with disruptions in sleep, constipation, and dysphagia at baseline demonstrated objective improvements Gains in skill and developmental milestones were consistent, durable, deepened over time and demonstrated improvements not expected based on natural history data Low-dose NGN-401 well-tolerated with favorable safety profile Company plans to provide an update of registration

    11/11/24 4:01:00 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

    Company to host webcast to review data on November 11 at 4:30 p.m. ET Late-breaker poster to be presented during Child Neurology Society Meeting on November 12 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will host a webcast to present interim efficacy data from the low-dose cohort of its ongoing Phase 1/2 clinical trial of NGN-401 gene therapy for pediatric patients with Rett syndrome on November 11, 2024 at 4:30 p.m. ET. Safety data from the low- and high-dose cohorts will also be shared. These data will also be presented in a late-breaking

    10/21/24 7:30:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neurogene Inc.

    SC 13G - Neurogene Inc. (0001404644) (Subject)

    12/11/24 4:05:09 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neurogene Inc.

    SC 13G/A - Neurogene Inc. (0001404644) (Subject)

    11/27/24 4:25:10 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neurogene Inc.

    SC 13G/A - Neurogene Inc. (0001404644) (Subject)

    11/14/24 4:53:08 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care